Wall Street Zen Upgrades Shattuck Labs (NASDAQ:STTK) to “Hold”

Shattuck Labs (NASDAQ:STTK) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Friday.

STTK has been the subject of several other reports. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Leerink Partners decreased their target price on shares of Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating for the company in a research note on Thursday, August 14th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.

Shattuck Labs Trading Up 2.6%

Shares of NASDAQ STTK opened at $1.55 on Friday. Shattuck Labs has a 12 month low of $0.69 and a 12 month high of $3.95. The company has a 50 day simple moving average of $0.89 and a two-hundred day simple moving average of $1.00. The stock has a market cap of $74.25 million, a price-to-earnings ratio of -1.28 and a beta of 1.64.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. Analysts forecast that Shattuck Labs will post -1.48 EPS for the current year.

Insider Buying and Selling at Shattuck Labs

In related news, Director Orbimed Advisors Llc purchased 6,306,127 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the acquisition, the director owned 5,255,106 shares in the company, valued at $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mona Ashiya purchased 6,306,127 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average cost of $0.87 per share, with a total value of $5,486,330.49. Following the acquisition, the director owned 5,255,106 shares in the company, valued at $4,571,942.22. This represents a -600.00% increase in their position. The disclosure for this purchase can be found here. 12.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Shattuck Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its holdings in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after acquiring an additional 31,355 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in Shattuck Labs in the 2nd quarter worth $44,000. Schonfeld Strategic Advisors LLC purchased a new stake in Shattuck Labs in the 4th quarter worth $45,000. Nuveen LLC purchased a new stake in Shattuck Labs in the 1st quarter worth $50,000. Finally, Bridgeway Capital Management LLC increased its holdings in Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after acquiring an additional 55,000 shares in the last quarter. Hedge funds and other institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.